Norfloxacin versus co-trimoxazole for treatment of urinary tract infections in adults: microbiological results of a coordinated multicentre study

Scandinavian Journal of Infectious Diseases
M RylanderR Svärd

Abstract

In a prospective, coordinated, double-blind multicentre trial, outpatients with urinary tract infections were randomized to 7 days b.i.d. treatment with norfloxacin 200 mg or 400 mg or trimethoprim/sulfamethoxazole. The most prevalent species was Escherichia coli (76.6%) followed by Staphylococcus saprophyticus (14.1%), the latter of which showed a marked seasonal variation with peak incidence during late summer. Minimum inhibitory concentrations (MICs) of 11 antibiotics for 651 pre-treatment bacterial strains were studied. Norfloxacin was found to be active against all isolates with MICs less than or equal to mg/l for gram-negative and less than or equal to 8 mg/l for gram-positive isolates. Reduced susceptibility to norfloxacin was seen in 2 strains of E. coli and 1 of Klebsiella pneumoniae from patients with persisting or relapsing infections following treatment with norfloxacin 400 mg b.i.d. Of other antibiotics tested, ampicillin, cephalothin and sulfamethoxazole were found to have poor activity against many gram-negative isolates while nalidixic acid and mecillinam lacked activity against all gram-positives. Cefotaxime, gentamicin, trimethoprim and trimethoprim/sulfamethoxazole were generally highly active against the iso...Continue Reading

References

Aug 1, 1977·Journal of Medical Microbiology·G Lidin-JansonK Lincoln
Jan 1, 1985·Scandinavian Journal of Infectious Diseases·A Forsgren
Apr 1, 1972·Antimicrobial Agents and Chemotherapy·C H O'CallaghanA H Shingler
Jan 1, 1983·Antimicrobial Agents and Chemotherapy·S R Norrby, M Jonsson
May 1, 1984·Reviews of Infectious Diseases·B Hovelius, P A Mårdh

❮ Previous
Next ❯

Citations

Feb 1, 1996·European Journal of Epidemiology·P F Schneider, T V Riley
May 1, 1990·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M López-Brea, T Alarcón
Dec 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J S Wolfson
Dec 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T J Babinchak, R J Fass
Sep 1, 1991·The Journal of Hospital Infection·H K van Saene, A Percival
Dec 30, 2014·Acta Biochimica Et Biophysica Sinica·Yuangang Qu, Fang Dong
Oct 12, 2010·The Cochrane Database of Systematic Reviews·Anca Zalmanovici TrestioreanuLeonard Leibovici
Oct 1, 1989·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·A BjörklindG Kronvall

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.